Form 13-F position report

ONCONOVA THERAPEUTICS INC COM

Reported by Ikarian Capital LLC

TRAW CUSIP 68232V801 Manager CIK 0001778253

Reported 0 shares, down 18,975 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2022
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 5 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 37000
2022-03-31 35000
2022-06-30 0
2024-12-31 874618
2025-03-31 65534
2025-06-30 42170
2025-09-30 52712
2025-12-31 766299
2026-03-31 1241000
2026-06-30 403217
2026-09-30 283921

Quarterly position history

How this manager's reported quarter-end position changed over time.

11 quarters
Quarterly reported position history for ONCONOVA THERAPEUTICS INC COM held by Ikarian Capital LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Unchanged 478,142 0 (0.0%) 0.03% $283,921 2026-11-16
Q2 2026 Reduced 478,142 -200,000 (-29.5%) 0.04% $403,217 2026-08-14
Q1 2026 Unchanged 678,142 0 (0.0%) 0.1% $1,241,000 2026-05-15
Q4 2025 Added 678,142 +649,649 (2280.0%) 0.06% $766,299 2026-02-18
Q3 2025 Unchanged 28,493 0 (0.0%) < 0.01% $52,712 2025-11-14
Q2 2025 Unchanged 28,493 0 (0.0%) < 0.01% $42,170 2025-08-14
Q1 2025 Reduced 28,493 -70,000 (-71.1%) < 0.01% $65,534 2025-05-15
Q4 2024 New 98,493 +98,493 (0.0%) 0.12% $874,618 2025-02-14
Q2 2022 Reduced 0 -18,975 (-100.0%) 0 $0 2022-08-12
Q1 2022 Added 18,975 +3,912 (26.0%) < 0.01% $35,000 2022-05-13
Q4 2021 Unchanged 15,063 0 (0.0%) < 0.01% $37,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

36 managers reported ONCONOVA THERAPEUTICS INC COM for Q2 2022.

Managers reporting ONCONOVA THERAPEUTICS INC COM in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 511,993 +28,369 < 0.01% $676,000 5 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 333,323 +11,580 < 0.01% $440,000 3 qtrs
BlackRock Inc Unchanged 248,881 0 < 0.01% $329,000 5 qtrs
TWO SIGMA ADVISERS LP Reduced 178,912 -173,400 < 0.01% $236,000 5 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 169,847 +6,878 < 0.01% $224,000 5 qtrs
MILLENNIUM MANAGEMENT LLC Added 61,390 +37,275 < 0.01% $81,000 3 qtrs
CITADEL ADVISORS LLC New 59,512 +59,512 < 0.01% $79,000 4 qtrs
STATE STREET CORPORATION Added 52,790 +2,400 < 0.01% $70,000 5 qtrs
Beacon Pointe Advisors LLC Added 51,976 +5,949 < 0.01% $68,000 5 qtrs
NORTHERN TRUST CORPORATION Unchanged 30,783 0 < 0.01% $41,000 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 12, 2022
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.